Epigenomics Reaches Financing Deal for up to $6.7M | GenomeWeb

NEW YORK (GenomeWeb News) – Epigenomics said that it has reached a financing agreement with YA Global Master SPV for up to €5 million ($6.7 million).

Under the terms of the agreement, YA Global will purchase over two years convertible notes with a total nominal amount of €5 million at a purchase price of 95 percent of the nominal amount. Epigenomics may issue the notes in tranches of €500,000 each, with each tranche comprising 500 convertible notes in the form of bearer bonds each with a nominal value of €1,000. The bonds are transferable only with approval by Epigenomics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.